ACADIA Pharmaceuticals Inc. P/Operating CF

P/Operating CF of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/Operating CF of ACADIA Pharmaceuticals Inc. is -323.66 (as of December 30, 2020)
  • P/Operating CF for the quarter ending December 30, 2020 was -323.66 (a 14.46% increase compared to previous quarter)
  • Year-over-year quarterly P/Operating CF increased by 139.83%
  • Annual P/Operating CF for 2020 was -323.66 (a 43.29% increase from previous year)
  • Annual P/Operating CF for 2019 was -225.89 (a 331.27% increase from previous year)
  • Annual P/Operating CF for 2018 was -52.38 (a -58.03% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of ACADIA Pharmaceuticals Inc.

Most recent P/Operating CFof ACAD including historical data for past 10 years.

Interactive Chart of P/Operating CF of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -323.66 -282.76 -208.55 -134.95 -323.66
2019 -225.89 -278.56 -101.18 -60.53 -225.89
2018 -52.38 -61.47 -51.06 -57.57 -52.38
2017 -124.79 -80.6 -57.83 -59.27 -124.79
2016 -54.47 -75.87 -64.82 -75.54 -54.47
2015 -103.32 -104.61 -140.68 -128.83 -103.32
2014 -173.45 -140.9 -131.87 -159.49 -173.45
2013 -208.67 -259.49 -278.08 -94.47 -208.67
2012 -40.7 -25.1 -19.97 -21.34 -40.7
2011 -10.85 -13.67 -16.26 -15.98 -10.85
2010 10.06 -13.85 -6.6 10.06

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.